SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Primary Results of the Randomized Phase 3 DESTINY-Breast02 Study: T-DXd vs. Physician’s Choice in HER2+ Unresectable and/or mBC Previously Treated With Trastuzumab Emtansine
By
SABCS 2022 Conference Coverage
FEATURING
Ian Krop
By
SABCS 2022 Conference Coverage
FEATURING
Ian Krop
154 views
January 5, 2023
Comments 0
Login to view comments.
Click here to Login
Videos